Design project is the first contract for the global alliance between GE Healthcare and iBio, which was announced in 2012.
April 9, 2013
by PLANT STAFF
CHALFONT ST GILES, UK and NEWARK, Del. – GE Healthcare has signed a contract to design a new plant-based multipurpose manufacturing facility for Bio-Manguinhos/Fiocruz in Brazil.
The design project is the first contract for the global alliance between GE Healthcare and iBio, which was announced in 2012. The alliance combines iBio’s plant-based manufacturing platform, iBioLaunch, with GE Healthcare’s capabilities in process design and start-to-finish biopharmaceutical and vaccine manufacturing technologies.
Bio-Manguinhos/Fiocruz is recognized internationally as a manufacturer of immunobiologicals for public health needs, primarily to support Brazilian Ministry of Health programs. It has invested in the development of bioprocess technologies such as iBioLaunch, through a co-development agreement with iBio and its research and development collaborator Fraunhofer USA Center for Molecular Biotechnology (FCMB).
GE Healthcare develops transformational medical technologies and services to meet the demand for increased access.
iBio develops and offers product applications of its iBioLaunch platform, which is a proprietary, transformative technology for the development and production of biologics using transient gene expression in unmodified green plants.